Abbott Gets EUA For Laboratory PCR Assay That Detects Four Viruses In One Test

雅培获得EUA用于实验室PCR检测,在一次检测中检测四种病毒

2021-03-06 06:13:57 RTTNews

本文共458个字,阅读需2分钟

Abbott said that it has received emergency use authorization from the U.S. Food and Drug Administration for the company's Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus or RSV in one test. It is an important tool because these viruses have similar symptoms but require different treatment approaches. This test is CE Marked and available in countries outside the U.S., the company said in a statement. The Alinity m Resp-4-Plex assay will allow healthcare workers to test for four viruses in one test, a critically important tool as flu presents with similar symptoms. The assay will run on the company's most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes. Abbott also announced that the EUA for the company's Alinity m SARS-CoV-2 test has been updated to include an asymptomatic claim - detecting COVID-19 in individuals who do not have symptoms. A recent study found that more than 60% of COVID-19 infections present as asymptomatic cases, which is why it's critical to catch those cases before they spread. For comments and feedback contact: editorial@rttnews.com Business News
雅培表示,已收到美国食品和药物管理局对该公司Alinity m Resp-4-Plex分子检测的紧急使用授权,用于在一次检测中检测和鉴别新型冠状病毒、甲型流感、乙型流感和呼吸道合胞病毒或RSV。 这是一个重要的工具,因为这些病毒有相似的症状,但需要不同的治疗途径。该公司在一份声明中说,这种测试是CE标记的,在美国以外的国家也可以使用。 Alinity m Resp-4-Plex检测将允许卫生保健工作者在一次检测中检测四种病毒,这是一个非常重要的工具,因为流感呈现出类似的症状。该检测将在该公司最先进的分子PCR平台Alinity m系统上运行,该系统提供快速、高容量的结果。 雅培还宣布,该公司Alinity m新型冠状病毒检测的EUA已经更新,纳入了一项无症状索赔--在没有症状的个人中检测新冠肺炎。 最近的一项研究发现,超过60%的COVID-19感染呈现为无症状病例,这就是为什么在这些病例传播之前抓住它们至关重要的原因。 如需评论和反馈,请联系:editorial@rttnews.com 商业新闻

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文